LABMED - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 164,556 | - | - | - | 8,157 | 3,930 | 247,982 | 539,350 |
| Profit before tax | 1,661 | -18,407 | 4,942 | -2,808 | -1,384 | -2,142 | 7,413 | 24,908 |
| Net profit | 1,131 | -18,407 | 4,720 | -2,808 | -1,384 | -2,142 | 7,079 | 23,712 |
| Equity | 125,536 | 107,129 | 111,849 | 109,041 | 107,657 | 105,515 | 112,594 | 136,306 |
| Liabilities | 56,938 | 50,798 | 0 | 0 | 72 | 2,175 | 39,886 | 61,796 |
| Non-current assets | 5 | 5 | 5 | 5 | 5 | 5 | 5,535 | 3,269 |
| Current assets | 182,280 | 138,658 | 111,844 | 109,036 | 107,724 | 107,685 | 146,945 | 194,833 |
| Total assets | 182,285 | 138,663 | 111,849 | 109,041 | 107,729 | 107,690 | 152,480 | 198,102 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | - | 1,105 | 7,786 |
| Social insurance contributions | - | - | - | - | - | - | 637 | 8,776 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -53.1% | - | - | - | - | -51.8% | +6210.0% | +117.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.6% | -13.3% | 4.2% | -2.6% | -1.3% | -2.0% | 4.6% | 12.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 0.9% | -17.2% | 4.2% | -2.6% | -1.3% | -2.0% | 6.3% | 17.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 0.7% | - | - | - | -17.0% | -54.5% | 2.9% | 4.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.0% | - | - | - | -17.0% | -54.5% | 3.0% | 4.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.5 | 0.5 | - | - | 0.0 | 0.0 | 0.4 | 0.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 25,645 | - | - | - | 4,079 | 1,965 | 78,309 | 134,838 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
LABMED - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-06-16 | 2026-06-18 | 20.15 |
LABMED - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
LABMED, UAB (code 111475280) is a Private Limited Liability Company engaged in wholesale of pharmaceutical and medical goods. In 2025, revenue reached €539.4K, compared with €248.0K in 2024 and €3.9K in 2023. The latest year therefore shows a strong expansion, with revenue up 117.5% year on year, while the 2-year increase reflects growth from a very small base. Net profit improved to €23.7K in 2025 from €7.1K in 2024, after a loss of €2.1K in 2023. Profitability also strengthened, with the net margin rising to 4.4% from 2.9% a year earlier. Total assets increased to €198.1K in 2025 from €152.5K in 2024, while equity rose to €136.3K and liabilities to €61.8K. The balance sheet remained conservative, with an equity ratio of 68.8% and debt-to-equity of 0.45. Asset turnover was 2.72x, ROE reached 17.4%, and ROA was 12.0%. Revenue per employee stood at €134.8K, with profit per employee of €5.9K.